Production of orally applicable new drug or drug combinations from natural origin capsaicinoids for human medical therapy

Current Pharmaceutical Design

Volumn 16, Issue 10, 2010, Pages 1197-1208

  Mózsik, Gyula ^a   Past, Tibor ^a   Dömötör, András ^a   Kuzma, Mónika ^a   Perjési, Pál ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

GI mucosal preventions; Natural capsaicin; NSAIDs; Patient

Indexed keywords

ACETYLSALICYLIC ACID; BETA CAROTENE; BETHANECHOL; CAPSAICIN; CAPSAICIN DERIVATIVE; CIMETIDINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DECANOIC ACID VANILLYLAMIDE; DIHYDROCAPSAICIN; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE; HOMOCAPSAICIN; HOMODIHYDROCAPSAICIN; INDOMETACIN; NIZATIDINE; NONIVAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROCAPSAICIN; OMEPRAZOLE; PENTAGASTRIN; PIRENZEPINE; PROSTACYCLIN; PROSTAGLANDIN E2; RANITIDINE; RESINIFERATOXIN; RETINOL; UNCLASSIFIED DRUG;

BELL PEPPER; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; MASS FRAGMENTOGRAPHY; NONHUMAN; PHYTOCHEMISTRY; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; STOMACH MUCOSA INJURY; STOMACH PROTECTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CAPSAICIN; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; GASTRIC ACID; GASTRIC MUCOSA; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; PHYTOTHERAPY; RATS;

EID: 77950899214     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210790945896     Document Type: Review

References (59)

1. Mózsik G. In: Mózsik Gy, Ed. Discoveries in Gastroenterology. From Basic Research the Clinical Perspectives (1960-2005). Budapest: Akadémiai Kiadó 2006; pp. 139-224.
2. Mózsik Gy, Abdel-Salam OME, Szolcsányi J. Capsaicin-Sensitive Afferent Nerves in Gastric Mucosal Damage and Protection. Budapest: Akadémiai Kiadó 1997.
3. Abdel-Salam OME, Szolcsányi J, Barthó L, Mózsik Gy. Sensory nerve-mediated mechanisms, gastric mucosal damage and its protection: a critical overview. Gastroprotection 1994; 2: 4-12.
4. Abdel-Salam OME, Mózsik Gy, Szolcsányi J. Capsaicin and its analogue resiniferatoxin inhibit gastric acid secretion in pylorusligated rats. Pharmacol Res 1995; 31: 341-345
5. Abdel-Salam OME, Mózsik Gy, Szolcsányi J. Effect of resiniferatoxin on stimulated gastric acid secretory responses in the rat. J Physiology (Paris) 1995; 88: 353-358
6. Abdel-Salam OME, Mózsik Gy, Szolcsányi J. Studies on the effect of intragastric capsaicin on gastric ulcer and on the prostacyclin-induced cytoprotection in rats. Pharmacol Res 1995; 32: 209-215 (Pubitemid 26072340)
7. Abdel-Salam OME, Bódis B, Karádi O, Szolcsányi J, Mózsik Gy. Modification of aspirin and ethanol-induced mucosal damage in rats by intragastric application of Resiniferatoxin. Inflammopharmacology 1995; 3: 135-147
8. Abdel-Salam OME, Bódis B, Karádi O, Szolcsányi J, Mózsik Gy. Nature of gastric H+ back-diffusion approached by cimetidine, vagotomy, RTX and sucralfate. Ceská Slovenská Gastroenterologie 1995; 49: 175-185
9. Abdel-Salam OME, Bódis B, Karádi O, Nagy L, Szolcsányi J, Mózsik Gy. Stimulation of capsaicin-sensitive sensory peripheral nerves with topically applied Resiniferatoxin decreases salicylate-induced gastric H+ back-diffusion in the rat. Inflammopharmacology 1995; 3: 121-133
10. Abdel-Salam OME, Szolcsányi J, Mózsik Gy. Differences in action of topical and system cystamine on gastric blood flow, gastric acid secretion and gastric ulceration in the rat. J Physiol (Paris) 1996; 90: 63-73.
11. Abdel-Salam OME, Szolcsányi J, Porszász R, Mózsik Gy. Effect of capsaicin and resiniferatoxin on gastrointestinal blood flow in rats. Eur J Pharmacol 1996; 305: 127-136 (Pubitemid 26197599)
12. Abdel-Salam OME, Mózsik Gy, Szolcsányi J. In: Mózsik Gy, Nagy L, Király Á, Eds. Cell Injury and Protection in Gastrointestinal Tract: from Basic Science to Clinical Perspectives. Dordrecht: Kluwer Academic Publisher 1997; pp. 95-105.
13. Abdel-Salam OME, Mózsik Gy, Szolcsányi J. In: Mózsik Gy, Nagy L, Király Á, Eds. Twenty Five Years of Peptic Ulcer Research in Hungary: from Basic Science to Clinical Practice 1971-1995. Budapest: Akadémiai Kiadó 1997; pp. 295-308.
14. Abdel-Salam OME, Szolcsányi J, Mózsik Gy. In: Gaginella T, Mózsik Gy, Rainsford KD, Eds. Biochemical Pharmacology as Approach to Gastrointestinal Disease: from Basic Science to Clinical Perspectives. Dordrecht: Kluwer Academic Publisher 1997; pp. 269-285
15. Abdel-Salam OME, Szolcsányi J, Mózsik Gy. The indomethacin-induced gastric mucosal damage in rats. Effect of gastric acid, acid inhibition, capsaicin-type agents and prostacyclin. J Physiol (Paris) 1997; 97: 7-19.
16. Abdel-Salam OME, Sleem AA, Hassan NB, Sharaf HA, Mózsik Gy. Capsaicin ameliorates hepatic injury caused by carbon tetrachloride in the rat. J Pharmacol Toxicol 2006; 1: 147-156
17. Abdel Salam OME, Czimmer J, Debreceni A, Szolcsányi J, Mózsik G. Gastric mucosal integrity: gastric mucosal blood flow and microcirculation. An overview. J Physiol 2001; 95: 105-127 (Pubitemid 33020225)
18. Abdel-Salam OME, Debreceni A, Mózsik Gy. Capsaicin-sensitive afferent sensory nerves in modulating gastric mucosal defense against noxious agents. J Physiol (Paris) 1999; 93: 443-454 (Pubitemid 30038594)
19. Mózsik Gy, Dömötör A, Abdel-Salam OME. Molecular pharmacological approach to drug actions on the afferent and efferent fibres of the vagal nerve in the gastric mucosal protection in rats. Inflammopharmacology 2006; 14: 243-249 (Pubitemid 46025542)
20. Mózsik Gy, Debreceni A, Abdel Salam OME, Szabó I, Figler M, Ludány A, et al. Small doses capsaicin given intragastrically inhibit gastric secretion in healthy human Jubjects. J Physiol(Paris) 1999; 93: 433-436 (Pubitemid 30038592)
21. Mózsik Gy, Szolcsányi J, Dömötör A. Capsaicin research as a new tool to approach of the human gastrointestinal physiology, pathology and pharmacology. (Review) Inflammopharmacology 2007; 15: 232-245 (Pubitemid 351196134)
22. Mózsik Gy, Szolcsányi J, Rácz I. Gastroprotection induced by capsaicin in healthy human subjects. World J Gastroenterol 2005; 11: 5095-5098 (Pubitemid 41410336)
23. Dömötör A, Peidl ZS, Vincze Á, Hunyady B, Szolcsányi J, Kereskay L, et al. Immunohistocemical distribution of vanilloid receptor (TRPV1), calcition generelated peptide (CGRP) and substance-P (SP) in the gastrointestinal mucosa of patients with different gastrointestinal disorders. Inflammopharmacology 2005; 13: 161-177
24. Dömötör A, Kereskay L, Szekeres Gy, Hunyady B, Szolcsányi J, Mózsik Gy. Participation of capsaicin-sensitive afferent nerves in the gastric mucosa of patients with Helicobacter pylori-positive ornegative chronic gastritis. Dig Dis Sci 2007; 52: 411-417 (Pubitemid 46202815)
25. Mcgettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A system review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644
26. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. (Review). Eur Heart J 2004; 25: 166-181
27. Todd PA, Clissold SP. Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic disease and pain states. Drugs 1990; 40: 91-137.
28. Couzin J. Nail-biting time for trials of COX-2 drug. Science 2004; 306: 1673-1675
29. Couzin J. Withdrawal of vioxx casts shadow over COX-1 inhibitors. Science 2004; 306: 3844-3850
30. Lenzer J. FDA is incapable of protecting of US against another vioxx". Brit Med J 2004; 329: 1253.
31. Green MD. Causation, Vioxx, and legal issues. Science 2005; 310: 973.
32. Lawler A. The law. Vioxx verdict: too little or too much science? Science. 2005 309: 1481.
33. Tanne JH. NEJM editor gives pretrial evidence in Vioxx case. BMJ 2006; 332: 255.
34. Tanne JH. NEJM stands by its criticism of Vioxx study. BMJ 2006; 332: 505.
35. Tanne JH. Court awards claimant 13.5m dollars in rofecoxib lawsuit. BMJ 2006; 332: 927.
36. Mózsik Gy, Dömötör A, Past T, Vas V, Perjési P, Kuzma M, et al. Capsaicinoids: From the Plant Cultivation to the Production of the Human Medical Drug. Budapest: Akadémiai Kiadó 2009.
37. Mózsik Gy, Past T, Abdel-Salam OME, Kuzma M, Perjési P. Interdisciplinary review for correlation between the plant origin capsaicinoids, non-steroidal antiinflammatory drugs, gastrointestinal mucosal damage and prevention in animals and human beings. Inflammopharmacology 2009; 17: 113-150
38. Szolcsányi J, Bartó L. In: Mózsik Gy, Hänninen O, Jávor T, Eds. Advances in Physiological Sciences. Gastrointestinal Defense Mechanisms. Oxford: Pergamon Press - Budapest, Akadémiai Kiadó. 1981; pp. 39-51.
39. Szolcsányi J. In: Chahl LA, Szolcsányi J, Lembech F, Eds. Antidromic Vasodilatation and Neurogenic Inflammation. Budapest: Akadémiai Kiadó 1984; pp. 27-56.
40. Szolcsányi J. In: Hakanson R, Sundler F, Eds. Tachykinin Antagonists. Amsterdam: Elsevier Co. 1985; pp. 45-54.
41. Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 1991; 43: 144-202.
42. Holzer P. Neural emergency system in the stomach. Gastroenterology 1998; 114: 823-839
43. Maggi CA. Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves. Prog Neurobiol 1995; 45: 1-98.
44. Mózsik Gy, Vincze Á, Szolcsányi J. Four response of capsaic-insensitive primary neurons to capsaicin and its analog. Gastric secretion, gastric mucosal damage and protection. J Gastroenterol Hepatol 2001; 16: 193-197
45. Basu SK, De AK. Capsicum: historical and botanical perspectives. London: Taylor and Francis Ltd. 2003; pp. 1-15.
46. Anu A, Peter KV. The chemistry of Paprika. Indian Species 2000; 37: 15-18.
47. Jurenitsch J, Kubelka W, Jentzsch K. Identification of cultivated taxa of Capsicum. Taxonomy, anatomy and composition of purgent principles. Plant Med 1979; 35: 175-183
48. Mózsik Gy, Past T, Perjési P, Szolcsányi J. Original Reports on Toxicology of Capsaicin I. The Testing of Capsaicin Natural USP 27 with Bacterial Reverse Mutation Tests. The date of final report 13 September 2007. Study code: 07/496-007M. Veszprém: LAB International Research Centre Hungary Ltd. 2008; pp. 1-33 (7 appendix).
49. Mózsik Gy, Past T, Perjési P, Szolcsányi J. Original Reports on Toxicology of Capsaicin II. Testing of Mutagenic Effect of Test Item Capsaicin Natural USP 27 by Mouse Micronucleus Test. The date of final report 12 October 2007. Study Code: 07/019-008E. Budapest: Toxic-Coop Ltd. 2008; pp. 1-18 (5 appendix).
50. Mózsik Gy, Past T, Perjési P, Szolcsányi J. Original Reports on Toxicology of Capsaicin III. 14-Day Oral Gavage Dose Range Finding Study with Capsaicin Natural USP 27 in the Rats. The date of final report 15 October 2007. Study Code: 07/018-100PE. Dunakeszi: Toxic-Coop Ltd. 2008; This report consists of 27 pages of text 51 pages of appendices.
51. Mózsik Gy, Past T, Perjési P, Szolcsányi J. Original Reports on Toxicology of Capsaicin IV. Oral Dose Range Finding Toxicity Study in Beagle Dogs with Capsaicin Natural USP 27. The date of final report 08 October 2007. Study Code: 07/496-100KE. Veszprém: LAB International Research Centre Hungary Ltd. 2008; pp. 1-26 (17 appendix).
52. Mózsik Gy, Past T, Perjési P, Szolcsányi J. Original Reports on Toxicology of Capsaicin V. Oral Dose Range Finding Toxicity Study of Capsaicin Natural USP 27 in Beagle Dogs (Supplementary Final Report). The date of final report 08 October 2007. Study Code: 07/496-100KE. Veszprém: LAB International Research Centre Hungary Ltd. 2008; pp. 1-20 (10 appendix).
53. Mózsik Gy, Past T, Perjési P, Szolcsányi J. Original Reports on Toxicology of Capsaicin VI. 28-Day Oral Toxicity Study of Capsaicin Natural USP 27 in Rats (Final Report). The date of final report 21 May 2008. Study Code: 07/018-100P. Dunakeszi: Toxic-Coop Ltd. 2008; This report consists of 31 pages text and 166 pages of appendix.
54. Mózsik Gy, Past T, Perjési P, Szolcsányi J. Original Reports on Toxicology of Capsaicin VII. 8-Day Oral Toxicity Study of Test Item Capsaicin Natural USP 27 in Beagle Dogs (Final Report). The date of final report 13 June 2008. Study Code: 07/496-100K. Veszprém: LAB International Research Centre Hungary Ltd. 2008; pp. 1-35 (90 appendix).
55. Mózsik Gy, Past T, Perjési P, Szolcsányi J. Original Reports on Toxicology of Capsaicin VIII. Amendment 2 to Study Plan. 28-Day Oral Toxicity Study of Test Item Capsaicin Natural USP 27 in Beagle Dogs. The date of final report 03 June 2008. Study Code: 07/496-100K. Veszprém: LAB International Research Centre Hungary Ltd. 2008; pp. 1-4.
56. Mózsik Gy, Past T, Perjési P, Szolcsányi J. Determination of capsaicin and dihydrocapsaicin content of dog's plasma by HPLCFLD method. In: Mózsik Gy, Past T, Perjési P, Szolcsányi J, Eds. Original Reports on Toxicology of Capsaicin VII. 8-Day Oral Toxicity Study of Test Item Capsaicin Natural USP 27 in Beagle Dogs (Final Report). The date of final report 13 June 2008. Study Code: 07/496-100K LAB. Veszprém: International Research Centre Hungary Ltd. 2008; pp. 1-35 (190 appendix).
57. Cortright DN, Szallasi A. TRP channels and pain. Curr Pharm Des 2009; 15(15): 1736-1749
58. Evangelista S. Role of calcitonin gene-related Peptide in gastric mucosal defence and healing. Curr Pharm Des 2009; 15(30): 3571-3576
59. Gunthorpe MJ, Szallasi A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr Pharm Des 2008; 14(1): 32-41.